The effect of cumin cyminum l. plus lime administration onweight loss and metabolic status in overweight subjects : a randomized double-blind placebo-controlled clinical trial

المؤلفون المشاركون

Taghizadah, Muhsin
Memarzadeh, Muhammad Rida
Shurayfi, Nisrin
Karmili, Fatimah
Kashan, Zuhrah Fakhriah
Asemi, Zatollah
Ubaydi, Fatimah

المصدر

Iranian Red Crescent Medical Journal

العدد

المجلد 18، العدد 8 (31 أغسطس/آب 2016)، ص ص. 1-8، 8ص.

الناشر

المستشفى الإيراني

تاريخ النشر

2016-08-31

دولة النشر

الإمارات العربية المتحدة

عدد الصفحات

8

التخصصات الرئيسية

الطب البشري

الملخص EN

Background: Limited data are available regarding the effects of combined administration of Cumin cyminum L.

and lime on weight loss and metabolic profiles among subjects with overweight subjects.

Objectives: The current study aimed to assess the effects of combined administration of Cumin cyminum L.

and lime on weight loss and metabolic profiles among subjects with overweight.

Patients and Methods: This randomized double-blind placebo-controlled clinical trial was conducted on 72 subjects with overweight, aged 18 - 50 years old.

Participants were randomly divided into three groups: Group A received high-dose Cumin cyminum L.

and lime capsules (75 mg each, n = 24), group B low-dose Cumin cyminum L.

and lime capsules (25 mg each, n = 24) and group C placebos (n = 24) twice daily for eight weeks.

Results: After eight weeks of intervention, compared with low-doseC.

cyminumL.

plus lime and placebo, taking high-doseC.

cyminum L.

plus lime resulted in significant weight loss (in the high-dose group: -2.1±1.7 vs.

in the low-dose group: -1.2±1.5 and in the placebo group: + 0.2 ± 1.3 kg, respectively; P < 0.001) and body mass index (-0.8 ± 0.6 vs.

-0.5 ± 0.5 and +0.1 ± 0.5 kg/m2 , respectively; P < 0.001).

In addition, administration of high-doseC.

cyminum L.

plus lime compared with low-doseC.

cyminum L.

plus lime and placebo, led to a significant reduction in fasting plasma glucose (FPG) (P < 0.001) and a significant rise in quantitative insulin sensitivity check index (QUICKI) (+ 0.02 ± 0.02 vs.

+ 0.01 ± 0.02 and 0.01 ± 0.01, respectively; P = 0.01).

Moreover, a significant decrease in serum triglycerides (-14.1 ± 56.2 vs.

+13.9 ± 36.8 and + 10.6 ± 25.1 mg/dL; respectively; P = 0.03), total-cholesterol (-18.4 ± 28.6 vs.

+8.6 ± 28.5 and -1.0 ± 24.8 mg/dL; respectively; P = 0.004) and low density lipoproteins- (LDL)-cholesterol levels (-11.8 ± 20.7 vs.

+6.5 ± 23.2 and -2.9 ± 20.4 mg/dL, respectively; P = 0.01) was observed following the consumption of high-dose C.

cyminum L.

plus lime compared with low-dose C.

cyminum L.

plus lime and placebo.

Conclusions: Results of the current study indicated that taking high-dose C.

cyminum L.

plus lime for eight weeks among subjects with overweight had beneficial effects on weight, BMI, FPG, QUICKI, triglycerides, total-cholesterol and LDL-cholesterol levels.

نمط استشهاد جمعية علماء النفس الأمريكية (APA)

Taghizadah, Muhsin& Memarzadeh, Muhammad Rida& Ubaydi, Fatimah& Shurayfi, Nisrin& Karmili, Fatimah& Kashan, Zuhrah Fakhriah…[et al.]. 2016. The effect of cumin cyminum l. plus lime administration onweight loss and metabolic status in overweight subjects : a randomized double-blind placebo-controlled clinical trial. Iranian Red Crescent Medical Journal،Vol. 18, no. 8, pp.1-8.
https://search.emarefa.net/detail/BIM-708512

نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)

Taghizadah, Muhsin…[et al.]. The effect of cumin cyminum l. plus lime administration onweight loss and metabolic status in overweight subjects : a randomized double-blind placebo-controlled clinical trial. Iranian Red Crescent Medical Journal Vol. 18, no. 8 (Aug. 2016), pp.1-8.
https://search.emarefa.net/detail/BIM-708512

نمط استشهاد الجمعية الطبية الأمريكية (AMA)

Taghizadah, Muhsin& Memarzadeh, Muhammad Rida& Ubaydi, Fatimah& Shurayfi, Nisrin& Karmili, Fatimah& Kashan, Zuhrah Fakhriah…[et al.]. The effect of cumin cyminum l. plus lime administration onweight loss and metabolic status in overweight subjects : a randomized double-blind placebo-controlled clinical trial. Iranian Red Crescent Medical Journal. 2016. Vol. 18, no. 8, pp.1-8.
https://search.emarefa.net/detail/BIM-708512

نوع البيانات

مقالات

لغة النص

الإنجليزية

الملاحظات

Includes bibliographical references : p. 8

رقم السجل

BIM-708512